...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Was checking out SEDAR...

RVXOT, yes all figures were $CAN. To both yours and Toinv's point, I agree this company is clearly being "run" by someone who doesn't understand how to realize the value of the science inherent to Zenith. With all the promise in the science it would seem that now would be an ideal time to be selling this company. Very many promising cancer therapies are sold for meaningful ROI at the ph2 stage. 

Share
New Message
Please login to post a reply